3-Iodo-5-(1-methylpyrrolidin-2-yl)pyridine | 64635-69-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 3-Iodo-5-(1-methylpyrrolidin-2-yl)pyridine
• CAS: 64635-69-4
• 化学式: C₁₀H₁₃IN₂
• 分子量: 288.13
• InChiKey: RXAHTJZPGQEDRZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  16.1
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• COMPOUNDS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF AMYLOID ASSOCIATED DISEASES
  申请人：Yang Jerry

  公开号：US20100260671A1

  公开（公告）日：2010-10-14

  The invention is in general directed to compounds, such as tannic acid, nicotine, nicotine derivatives and pyrrolid derivatives of nicotine, and methods for diagnosing, preventing or alleviating the symptoms of amyloid-associated diseases, for example, neuronal diseases, such as, for example, Alzheimer's disease, compounds and methods for inhibiting ion channel activity of beta amyloid, and methods of diagnostic imaging of A/3 fibrils.

  本发明通常涉及化合物，例如单宁酸、尼古丁、尼古丁衍生物和吡咯烷基衍生物，以及用于诊断、预防或缓解淀粉样相关疾病的症状的方法，例如神经元疾病，例如阿尔茨海默病，用于抑制β淀粉样物离子通道活性的化合物和方法，以及A/3纤维的诊断成像方法。
• Nicotinic attenuation of CNS inflammation and autoimmunity
  申请人：DIGNITY HEALTH

  公开号：US10080747B2

  公开（公告）日：2018-09-25

  The present invention relates to methods of treating and/or ameliorating the severity of inflammation and autoimmunity in the central nervous system (CNS). In one embodiment, the present invention provides a method of treating multiple sclerosis by administering a therapeutically effective dosage of nicotine, or a pharmaceutical equivalent, analog, derivative, or salt thereof.

  本发明涉及治疗和/或改善中枢神经系统（CNS）炎症和自身免疫严重程度的方法。在一个实施方案中，本发明提供了一种通过施用治疗有效剂量的尼古丁或其药物等效物、类似物、衍生物或盐来治疗多发性硬化症的方法。
• LIPOPHILIC ACTIVE AGENT INFUSED COMPOSITIONS WITH REDUCED FOOD EFFECT
  申请人：Poviva Corp.

  公开号：EP3780976A1

  公开（公告）日：2021-02-24
• COMPOSITIONS INFUSED WITH NICOTINE COMPOUNDS AND METHODS OF USE THEREOF
  申请人：Poviva Corp.

  公开号：EP3781163A1

  公开（公告）日：2021-02-24
• ENHANCEMENT OF DELIVERY OF LIPOPHILIC ACTIVE AGENTS ACROSS THE BLOOD-BRAIN BARRIER AND METHODS FOR TREATING CENTRAL NERVOUS SYSTEM DISORDERS
  申请人：Poviva Corp.

  公开号：EP3810135A1

  公开（公告）日：2021-04-28